Table 2 Baseline demographic and clinical characteristics of the enrolled population
Characteristic | Placebo (n=88) | Apremilast BID | Total (N=352) | ||
|---|---|---|---|---|---|
| Â | Â | 10 mg (n=89) | 20 mg (n=87) | 30 mg (n=88) | Â |
Age (years) | 44.1 ± 13.7 | 44.4 ± 14.0 | 44.6 ± 12.6 | 44.1 ± 14.7 | 44.3 ± 13.7 |
Male | 53 (60.2) | 63 (70.8) | 55 (63.2) | 50 (56.8) | 221 (62.8) |
Race | Â | Â | Â | Â | Â |
   White | 83 (94.3) | 82 (92.1) | 82 (94.3) | 80 (90.9) | 327 (92.9) |
   Black | 1 (1.1) | 2 (2.2) | 1 (1.1) | 2 (2.3) | 6 (1.7) |
   Asian | 4 (4.5) | 3 (3.4) | 2 (2.3) | 4 (4.5) | 13 (3.7) |
   Other | 0 (0.0) | 2 (2.2) | 2 (2.3) | 2 (2.3) | 6 (1.7) |
Height (cm) | 171.2 ± 8.6 | 171.5 ± 10.2 | 171.7 ± 9.6 | 171.2 ± 10.7 | 171.5 ± 9.6 |
Weight (kg) | 90.3 ± 21.4 | 95.7 ± 23.2 | 89.9 ± 20.2 | 91.2 ± 23.1 | 91.8 ± 22.0 |
BMI (kg/m2) | 30.8 ± 6.7 | 32.5 ± 7.4 | 30.4 ± 6.2 | 31.1 ± 7.8 | 31.2 ± 7.1 |
Total PASI score | 18.1 ± 5.7 | 18.1 ± 6.3 | 18.5 ± 7.3 | 19.1 ± 7.1 | 18.5 ± 6.6 |
BSA | 21.0 ± 11.2 | 21.3 ± 11.4 | 20.7 ± 12.4 | 25.0 ± 15.4 | 22.0 ± 12.8 |
+ History PsA | 17 (19.3) | 20 (22.5) | 16 (18.4) | 21 (23.9) | 74 (21.0) |
Plaque psoriasis history (years) | 19.6 ± 11.6 | 18.0 ± 12.4 | 19.2 ± 12.2 | 19.2 ± 12.0 | 19.0 ± 12.0 |
Previous systemic therapy for psoriasis | 39 (44.3) | 47 (52.8) | 43 (49.4) | 47 (53.4) | 176 (50.0) |